Citi analyst Samantha Semenkow raised the firm’s price target on Cabaletta Bio to $30 from $26 and keeps a Buy rating on the shares. The analyst says initial data for CABA-201 in myositis and lupus are expected this quarter. Despite the crowding in autoimmune CAR-T clinic trials, Cabaletta is a first mover in the space, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio price target raised to $33 from $31 at Morgan Stanley
- Cabaletta Bio price target lowered to $34 from $35 at Wells Fargo
- Cabaletta Bio price target raised to $30 from $25 at H.C. Wainwright
- Cabaletta Bio price target raised to $32 from $31 at Stifel
- Cabaletta Bio files automatic mixed securities shelf
